Molecular Partners ^Partner

Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland. Founded in 2004 as a spin-off from the University of Zürich, the company specializes in developing DARPin therapeutics, a unique class of small proteins designed to address unmet medical needs in oncology, immuno-oncology, ophthalmology, and infectious diseases.

The company's core offering is its DARPin platform, which creates multi-specific and highly stable protein therapeutics. These proteins can target multiple pathways simultaneously, making them suitable for complex diseases. Molecular Partners has two DARPin molecules in clinical development and a broad preclinical pipeline targeting various conditions. The company collaborates with industry leaders like Allergan and Amgen to advance its therapeutic candidates, emphasizing partnerships with pharmaceutical companies, clinical research organizations, and academic institutions.

Molecular Partners is committed to transforming lives through innovative therapies, focusing on collaboration and patient-centric innovation.